SBI Securities’s Addex Therapeutics ADXN Stock Holding History

SBI Securities’s Portfolio ADXN Stock Details ADXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$389	Buy	141 +140	+14,000%	+$624	﹤0.01%	3195
2026 Q2	$6	Hold	1	–	–	﹤0.01%	3955
2026 Q1	$6	Hold	1	–	–	﹤0.01%	3886
2025 Q4	$8	Sell	1 -4	-80%	-$34	﹤0.01%	3887
2025 Q3	$47	Hold	5	–	–	﹤0.01%	3735
2025 Q2	$47	Hold	5	–	–	﹤0.01%	3731
2025 Q1	$37	Hold	5	–	–	﹤0.01%	3718
2024 Q4	$35	Buy	+5	New	+$46	﹤0.01%	3706

SBI Securities's ADXN Position: Q3 2026 in Review

SBI Securities increased its Addex Therapeutics (ADXN) stake by 14,000% in Q3 2026, buying an estimated $624 and bringing the position to 141 shares worth $389. The position accounts for ﹤0.01% of the portfolio, ranked #3195.

SBI Securities first reported a position in ADXN in Q4 2024 and has held it in 8 quarters since. 1 fund tracked by Wall St. Rank holds ADXN as of Q3 2026.

SBI Securities held 141 shares of Addex Therapeutics worth $389 as of Q3 2026.
SBI Securities bought 140 Addex Therapeutics shares in Q3 2026, an estimated $624.
Addex Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3195 holding.
SBI Securities first reported a position in Addex Therapeutics in Q4 2024 and has held it in 8 quarters since.
1 fund tracked by Wall St. Rank held Addex Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.